Axonics, Inc. (NASDAQ:AXNX – Get Free Report) CFO Kari Leigh Keese sold 2,961 shares of Axonics stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $69.41, for a total transaction of $205,523.01. Following the transaction, the chief financial officer now directly owns 40,362 shares of the company’s stock, valued at approximately $2,801,526.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Axonics Trading Up 0.2 %
Axonics stock traded up $0.15 during midday trading on Thursday, reaching $69.63. The stock had a trading volume of 347,075 shares, compared to its average volume of 731,744. The company has a fifty day moving average price of $68.90 and a two-hundred day moving average price of $68.04. Axonics, Inc. has a 12 month low of $48.30 and a 12 month high of $69.91. The company has a market capitalization of $3.55 billion, a P/E ratio of -217.00 and a beta of 0.81.
Axonics (NASDAQ:AXNX – Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.10 by $0.03. Axonics had a negative return on equity of 0.27% and a negative net margin of 0.42%. The firm had revenue of $114.57 million during the quarter, compared to the consensus estimate of $112.83 million. During the same quarter in the previous year, the company posted ($0.15) earnings per share. The company’s quarterly revenue was up 23.3% on a year-over-year basis. On average, equities research analysts predict that Axonics, Inc. will post 0.24 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Separately, Needham & Company LLC reissued a “hold” rating on shares of Axonics in a research report on Monday, August 5th. Eight research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Axonics currently has a consensus rating of “Hold” and an average target price of $69.57.
Read Our Latest Research Report on Axonics
About Axonics
Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.
Featured Articles
- Five stocks we like better than Axonics
- Stock Dividend Cuts Happen Are You Ready?
- When Is the Best Time to Invest in Mutual Funds?
- P/E Ratio Calculation: How to Assess Stocks
- Is NVIDIA Stock in a Correction or Consolidation?
- What Does a Stock Split Mean?
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Axonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics and related companies with MarketBeat.com's FREE daily email newsletter.